These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32233616)

  • 21. Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-analysis.
    Mittal A; Tamimi F; Molto C; Meti N; Al-Showbaki L; Wilson BE; Amir E
    Crit Rev Oncol Hematol; 2023 Jan; 181():103880. PubMed ID: 36435297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
    Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
    Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers].
    Liao N; Zhang GC; Li XR; Yao M; Wang K
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):943-5. PubMed ID: 19460715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substituting adjuvant trastuzumab emtansine for Herceptin improves survival in patients with human epidermal growth factor receptor 2-positive breast cancer.
    Printz C
    Cancer; 2019 Apr; 125(8):1213. PubMed ID: 30934124
    [No Abstract]   [Full Text] [Related]  

  • 26. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 27. Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer.
    Chung C
    Am J Health Syst Pharm; 2022 May; 79(10):717-718. PubMed ID: 35021198
    [No Abstract]   [Full Text] [Related]  

  • 28. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond.
    García-Alonso S; Ocaña A; Pandiella A
    Trends Cancer; 2020 Feb; 6(2):130-146. PubMed ID: 32061303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Small HER2-positive breast cancer: which prognosis and which adjuvant treatment?].
    Gonçalves A; Vassilakopoulou M; Spano JP
    Bull Cancer; 2013 Sep; 100(9):847-56. PubMed ID: 23899689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
    Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
    Ohzawa H; Sakatani T; Niki T; Yasuda Y; Hozumi Y
    Breast Cancer; 2014 Sep; 21(5):563-70. PubMed ID: 23108629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant pertuzumab improves early breast cancer outcomes.
    Das M
    Lancet Oncol; 2017 Jul; 18(7):e378. PubMed ID: 28625555
    [No Abstract]   [Full Text] [Related]  

  • 34. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer.
    Kim M; Agarwal S; Tripathy D
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):27-33. PubMed ID: 24335887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
    Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
    Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Hassett MJ; Li H; Burstein HJ; Punglia RS
    Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
    Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.